Pulmonary hypertension (PH) is a complex and often misunderstood disease. It is characterized by elevated pulmonary artery pressure and pulmonary vascular resistance, leading to right ventricular failure. This article aims to provide an in-depth understanding of the fundamentals of PH.
PH is a pathophysiological disorder that involves multiple pathways. These include vasoconstriction, vascular remodeling, thrombosis, and inflammation. The endothelial dysfunction leads to an imbalance between vasodilators and vasoconstrictors, contributing to increased pulmonary vascular resistance.
PH often presents insidiously, with nonspecific symptoms such as dyspnea on exertion, fatigue, and syncope. As the disease progresses, right ventricular failure symptoms such as edema and ascites may become apparent. Early diagnosis is crucial to improve patient outcomes.
Diagnosis of PH involves a combination of clinical assessment, echocardiography, and right heart catheterization. An elevated mean pulmonary artery pressure of >20mmHg at rest, as measured by right heart catheterization, is diagnostic of PH. Echocardiography serves as a non-invasive screening tool, while right heart catheterization confirms the diagnosis.
Management of PH involves addressing the underlying cause, symptom control, and slowing disease progression. Therapies include vasodilator drugs, anticoagulants, diuretics, and in severe cases, lung transplantation. A multidisciplinary approach is essential for optimal patient care.
Understanding the fundamentals of PH is vital for early diagnosis and effective management. It is a complex disease that requires a comprehensive diagnostic approach and a multidisciplinary management strategy. By increasing our understanding of PH, we can improve patient outcomes and quality of life.
1.
Scholastic performance is a key concern for young cancer patients, study finds
2.
With the use of a novel sequencing technique, pediatric bone marrow transplant mortality can be predicted by analyzing lung microbiomes.
3.
Vistagen's Anxiety Disorder Drug Misses Main Goal in Late-stage Trial, Shares Plummet
4.
PRO Data Strengthen Case for Dato-DXd in First-Line TNBC
5.
Study looks into cancer-related harmful communication.
1.
Unraveling the Mysteries of Lymphoma: A Journey into the Unknown
2.
Expanding Oncology Frontiers: Rare Cancers, Breakthroughs, and Precision Medicine Advances
3.
Colorectal Cancer Uncovered: CME, Case Studies, and Clinical Strategies
4.
Understanding Carcinoid Tumors: Diagnosis, Symptoms, and Treatment Options
5.
Risk Assessment of Cancer-Associated Thrombotic Events
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
4.
Oropharyngeal Cancer in Relation to HPV Status
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation